[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 5, 2003

Pharmacist Care for Reactive Airway DiseasePharmacist Care for Reactive Airway Disease

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;289(9):1103-1106. doi:10.1001/jama.289.9.1103-a

To the Editor: Dr Weinberger and colleagues1 implemented the same protocol for patients with both asthma and COPD. However, there are many differences with regard to the appropriateness of peak-flow-monitoring, clinical interventions and outcomes, health-related quality of life, knowledge, self-efficacy, compliance, etc between these 2 diseases. In addition, the distinction between asthma and COPD was only based on smoking history and age. The increase in ED visits and hospital admissions within the pharmaceutical care group might also be attributed to increased knowledge followed by increased self-monitoring (peak flow and symptoms). Administering a sufficient evaluation of self-efficacy would have been a useful approach.2 Furthermore, the authors did not compare their results with studies that have supported pharmaceutical care programs.24

First Page Preview View Large
First page PDF preview
First page PDF preview
×